Part of trial team that obtained final opinion of infringement and validity for four asserted patents after bench trial relating to Janssen Biotech’s blockbuster drug IMBRUVICA®, which was generating $9.8 billion in annual revenue at the time of settlement, enjoining two generic defendants from entering the market prior to the expiration of the asserted patents.
Represented Janssen Biotech in patent litigation against five generic defendants involving its blockbuster drug IMBRUVICA®, which was generating $9.8 billion in annual revenue at the time of settlement.
Reached favorable settlement in representation of Janssen Products, L.P. in a patent infringement action against two generic defendants involving HIV drug PREZISTA®, which was doing $2.2 billion in annual revenues at the time of settlement.
Reached favorable settlement in representation of Janssen Products, L.P. in a patent infringement action against six generic defendants involving chemotherapy drug YONDELIS®.
Represented Janssen Products, L.P. in patent litigation involving HIV drug SYMTUZA® that resulted in favorable consent judgments against seven generic defendants, admitting infringement and enjoining defendants from entering the market early.
